We expect to see more that are tailored to improve the immune response against emerging variants.

🐦🔗: nitter.eu/EMA_News/status/1595

Preliminary data show that adapted increase the neutralisation of subvariants compared to original COVID-19 vaccines. Revaccinations with the adapted vaccines increase protection against disease.

🐦🔗: nitter.eu/EMA_News/status/1595

We see no major increase in case rates in the EU due to high immunity in population following vaccination & natural infection. However, this could change rapidly as we are getting into winter months.
❗️The virus is keeping a fast pace in its evolution.

🐦🔗: nitter.eu/EMA_News/status/1595

📢Uptake of additional vaccine doses in last few months is rather disappointing: the European average is only 29% revaccinations in people most at risk.
❗️It is of concern that people at risk of hospitalisation or severe are not adequately protected.

🐦🔗: nitter.eu/EMA_News/status/1595

The risk of severe increases exponentially if you are 60 years or older.
❗️The older you are, the more you are at risk, and vaccines can save your life.
We encourage you to get vaccinated or re-vaccinated especially if you belong to higher risk groups.

🐦🔗: nitter.eu/EMA_News/status/1595

: EMA is contributing to international activities to advance development of mucosal vaccines that are administered via the nose, mouth or inhalation, which could increase their ability to prevent infection and to block transmission.

🐦🔗: nitter.eu/EMA_News/status/1595

Follow

Heavy menstrual bleeding with mRNA : our safety committee noted that most of cases appeared to be temporary & non-serious. There is no evidence showing the menstrual disorders experienced by some people have an impact on reproduction & fertility.

🐦🔗: nitter.eu/EMA_News/status/1595

· · mirror-bot · 1 · 0 · 0

EMA’s Emergency Task Force reviewed numerous studies which reaffirm that are safe and provide protection for pregnant people & the babies they carry.
❗️Newborns are particularly vulnerable to the dire consequences of following infection.

🐦🔗: nitter.eu/EMA_News/status/1595

There are high concerns that new emerging subvariants are escaping neutralisation by available monoclonal antibody medicines against . We will review all available data to issue new recommendations to healthcare professionals.

🐦🔗: nitter.eu/EMA_News/status/1595

We are in contact with developers to advance next generation monoclonal antibodies against based on innovative clinical study design. We will discuss this with @US_FDA and international experts in December 2022.

🐦🔗: nitter.eu/EMA_News/status/1595

Outbreak of Sudan virus in Uganda: We are supporting the @WHO for rapid implementation of to establish the efficacy and safety of therapeutics and vaccines.

🐦🔗: nitter.eu/EMA_News/status/1595

Sign in to participate in the conversation
Mastodon

A Mastodon forum for the discussion of European Union matters. Not run by the EU. Powered by PleromaBot, Nitter and PrivacyDev.net.